Servier is an independent Group governed by a non-profit foundation, with our headquarters in France (Suresnes). Operating in 150 countries, we have 21,900 employees worldwide and a revenue of 5.3 billion euros in 2022/23. Entirely independent, we invest each year over 20% of brand-name revenue in R&D, and all profits are used forfurther development. Our R&D is focused on five main therapeutic areas: oncology, neuroscience, immuno-inflammation, cardiometabolism and venous diseases. We have long been a leader in the field of cardiology, and we aim to become a renowned and innovative player in oncology. We have 16 manufacturing sites, 4 research centers and 15 clinical development centers all around the world. 520 million boxes of brand-name medicines have been produced in our facilities in 2022/2023., for the benefits of the patients worldwide.
We are committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to transmit to future generations a world that can ensure access to quality health care for all. We aim to create a significant positive social impact for a sustainable world.
Servier is present on Bulgarian pharmaceutical market for 32 years, with a team of 80 professionals, who love what they do.We are proud that Servier Bulgaria has been recognized as Best Place To Work in 2023.We are here to improve patients’ lives in Bulgaria and to drive progress in health care.
In case of an adverse drug reaction associated with Servier product, please contact us by e-mail: pharmacovigilance.bg@servier.com, by fax: +359 2 921 57 38 or inform directly the Pharmacovigilance department of Servier Medical, Bulgaria on tel.: +359 2 921 57 55.